following is a collection of featured thoracic articles
from the Journal of Thoracic and Cardiovascular
Surgery (JTCVS). To read the latest issue, or
browse the feature video library and other journal
highlights, please visit www.jtcvs.org.
for monthly AATS Journal Alerts here. (Please note you will be asked to login
or create an account for AATS Online.)
previous AATS Journal Alerts here.
add email@example.com to your Safe Senders list.
following concurrent chemotherapy and high-dose radiation
for stage IIIA non–small cell lung cancer
Donington, MD, Rebecca Paulus, BS, Martin J. Edelman,
MD, Mark J. Krasna, MD, Quynh-Thu Le, MD, PhD, Mohan
Suntharalingam, MD, Billy W. Loo Jr., MD, PhD, Chen Hu,
PhD, Jeffrey D. Bradley, MD, for the NRG Oncology Lung
Lobectomy was performed safely following
full-dose concurrent chemoradiotherapy in these
multi-institutional prospective trials.
High-dose induction chemoradiation for lung cancer: The
past is prologue
Nasser Altorki, MD, Brendon Stiles, MD
data from 2 phase 2 trials with chemotherapy plus
high-dose radiation before stage IIIA NSCLC surgery
show that lobar resection can be done safely but
complex resections carry 20% mortality.
Burn, baby, burn
Joanna Sesti, MD, Subroto Paul, MD,
preoperative radiation (60 Gy) can be given to
patients with stage IIIA non–small cell lung cancer
with acceptable mortality at selected centers.
resection compared with stereotactic body radiation
therapy and ablation for early stage non–small cell lung
cancer: A National Cancer Database study
Jing Wu, MD,
Harrison X. Bai, MD, Lilian Chan, MS, Chang Su, MS,
Paul J. Zhang, MD, Li Yang, MD, Zishu Zhang, MD
Our results suggest SLR may be
associated with increased OS in patients with
early-stage NSCLC compared with SBRT or ablation.
The wizard of OS: Is overall survival better after
sublobar resection versus stereotactic radiation or
Jules Lin, MD, FACS, FCCP
authors report better survival with sublobar
resection versus stereotactic radiation or
ablation, although data in the National Cancer
Database are limited and future prospective studies
To wedge or not to wedge
Chadrick E. Denlinger, MD
retrospective review of a large administrative
database suggests that the most effective alternative
to lobectomy for early-stage lung cancer is a
sublobar resection followed by SBRT and thermal
Can big data effectively answer important clinical
Michael Lanuti, MD
of sublobar resection, SBRT, or percutaneous
thermal ablation for treatment of early stage NSCLC
are difficult in a nonrandomized setting.
resection for the non–small cell lung cancer in the
posterior segment of left upper lobe.
of robotic versus thoracoscopic segmentectomy for
early-stage lung cancer: A multi-institutional propensity
MD, PhD, Chun Chen, MD, PhD, Jian Hu, MD, PhD, Yu Han,
MD, Maosheng Huang, MD, Jie Xiang, MD, Hecheng Li, MD,
Robotic segmentectomy resulted in
comparable short-term outcomes compared with VATS
segmentectomy for early NSCLC. A potential benefit of
robotics might relate to an improved N1 lymph node
Robot-assisted segmentectomy is safe and expensive—What
is the debate?
Kimberly J. Song, MD, Raja M. Flores,
segmentectomy is safe but expensive and has not
been shown to provide clinical benefits relative to
video-assisted thoracoscopic surgery.
Video-assisted thoracoscopic surgery versus robotic
assisted surgery: Are we asking the right question?
Samuel S. Kim, MD, FACS, Ankit Bharat,
video-assisted thoracoscopic and robotic
segmentectomy are effective and safe in the hands
of expert surgeons in treating early lung cancer.
CANCER: INVITED EXPERT OPINION
considerations for neoadjuvant immunotherapy in non–small
cell lung cancer
Stiles, MD, Boris Sepesi, MD, Stephen R. Broderick, MD,
Matthew J. Bott, MD
Intense interest exists in preoperative
immunotherapy for patients with surgically resectable
lung cancer. Surgeons should be actively involved in
trial design, patient selection, and outcome
Why does neoadjuvant therapy suddenly make sense for
early stage non–small cell lung cancer?
Jessica Donington, MD, MSCR
of neoadjuvant immune checkpoint inhibitors have
generated great enthusiasm, but we must be
cognizant of the potential for negative influence
on short-term surgical outcomes in early-stage
survival after lung transplantation for adults requiring
preoperative invasive mechanical ventilation: A national
Hamilton, MD, MAS, Gabriela R. Dincheva, BS, Michael A.
Matthay, MD, Steven Hays, MD, Jonathan P. Singer, MD,
MS, Marek Brzezinski, MD, Jasleen Kukreja, MD, MPH
The last decade has shown significant
improvements in survival for lung transplantation in
mechanically ventilated recipients.
Survival of the fittest: Survival improved in patients
on mechanical ventilation pretransplant, but frailty
survival has improved in patients on mechanical
ventilation pre-lung transplant, assessing frailty
is critical, as these patients continue to have
worse survival than nonventilated patients.
Rage against the machine (ventilator that is)
David B. Erasmus, MB, ChB, MD, Si M.
Pham, MD, Kevin P. Landolfo, MD
improvements in recipient survival following lung
transplant with pretransplant mechanical
ventilation, the quest for better bridging